Shanghai Yanhua Smartech Group Co., Ltd. (SZSE:002178) agreed to acquire 45% stake in Beijing Taihe Kang Medical Biotechnology Co., Ltd. from Beijing Zhonghui Ganding Investment Management Co., Ltd. for approximately CNY 180 million on October 30, 2019. Prior to the transaction, Shanghai Yanhua Smartech Group Co., Ltd. did not hold a stake in Beijing Taihe Kang Medical Biotechnology Co., Ltd.; after the transaction was completed, it will hold a 45% stake in Beijing Taihe Kang Medical Biotechnology Co., Ltd. For the year ended December 31, 2018, Beijing Taihe Kang Medical Biotechnology Co., Ltd. has total assets of CNY 178.9 million, net assets of CNY 11.4 billion, revenue of CNY 50.7 million and net profit of CNY 36.7 million. Shanghai Yanhua Smartech Group Co., Ltd. (SZSE:002178) completed the acquisition of 45% stake in Beijing Taihe Kang Medical Biotechnology Co., Ltd. from Beijing Zhonghui Ganding Investment Management Co., Ltd. on December 31, 2019. Recently, the management level of the company signed the share transfer agreement and supplementary agreement with Zhonghui Ganding. The company will acquire 45% stake in Taihekang for CNY184.5 million. The parties reached a new agreement under the ‘supplement agreement’ concerning the payment method of the first payment. The owners of the 8 sets of real estate are the company’s 8 wholly-owned subsidiaries. The company and Zhonghui Ganding agreed for the company to directly transfer 100% stake in the 8 subsidiaries to Zhonghui Ganding to serve as the payment of the first transfer price. The 10th session of Shanghai Yanhua Smartech Group Co., Ltd.'s 5th directorate approved the deal.